RE: French RNS24 Feb 2021 10:43
So this LFT test/development will Dovetail nicely with any announcements due (Phase 1 extension or Phase 2 or £22B Tender or something else???)
also from below:-
"It can broaden the revenue outlook related to COVID-19, as demand for testing will continue to grow."
Development of a COVID-19 LFT test
The Group is continuing its development work on an IgG antibody lateral flow test (LFT) which will be used as a rapid antibody test intended for professional use. An LFT is an easy-to-use diagnostic device, used to confirm the presence or absence of a pathogen or biomarker, and it takes about 10 to 20 minutes or less to get a result.
The Group plans to launch its LFT in the second quarter of 2021, a little later than expected, as it has made the strategic decision to develop a new generation of LFT to detect the neutralizing antibodies generated by a successful immunization and thus to help control the effectiveness of future vaccines 3. The Group believes this is a good illustration of how it can broaden the revenue outlook related to COVID-19, as demand for testing will continue to grow."